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To verify the idea that extracellular free oligosaccharides might be able to reflect the functional status 
of the endoplasmic reticulum (ER) and lysosomal-endosomal system, HPLC-profiles of serum-derived free 
oligosaccharides (FOS) in human healthy aging, acute myeloproliferative neoplasms, and cardiovascular 
pathologies were compared with intracellular glycans. After plasma deproteinization and FOS purification 
the oligosaccharides were labelled with anthranilic acid, separated into the neutral and charged with Qae 
Sephadex (Q25-120) chromatography and analysed using high-performance liquid chromatography (HPLC). 
the charged FOS were digested with a sialidase and compared with free oligosaccharides from transferrin 
for structural decoding. HPLC-profiles of serum-derived FOS revealed mild delay of the dolichol phosphate 
cycle in ER, moderate intensification of ER-associated degradation (ERAD) and degradation in endosomal-
lysosomal system with aging; an inhibition of the dolichol phosphate cycle, intensification of ERAD and 
increasing of lysosomal exocytosis in acute myeloproliferative neoplasms; intensification of ERAD and gly-
cocojugate degradation with endosomal-lysosomal system in cardiovascular diseases. as serum free oligo-
saccharides are able to reflect specifically perturbations in ER and endosomal-lysosomal system under wide 
range of stressors they can serve as extracellular markers of functionality of these organelles.
K e y  w o r d s: free oligosaccharides (FOS), HPLC-profiles of glycans, ER stress, ER-associated protein 
degradation (eraD), endosomal-lysosomal disturbances, glycomarkers.
The multilayered protein quality assurance system encompasses almost all cellular or-ganelles, a network of biochemical processes 
and a multiplex of intracellular and extracellular 
signaling cascades [1-5]. At the centre of this wide 
cellular landscape there are two main hubs – the en-
doplasmic reticulum (ER) and lysosomal-endosomal 
system. The former is responsible for quality-reliable 
guarantee of newly synthesized proteins, the latter – 
for effective degradation of mature proteins, incor-
rectly folded proteins and their adducts.
The endoplasmic reticulum provides an inter-
connected space for translation, co-translational and 
post-translational modifications, folding and assem-
bling of secreted, organelle-targeted and membrane 
proteins. Only properly folded and assembled pro-
teins can be transported out of the ER via the Golgi 
apparatus and cytosol to the endpoint of their func-
tional actions – cellular organelles, plasma mem-
brane and extracellular space. Native protein con-
formation is achieved due to unique environment of 
the ER lumen and a specific co-translational modifi-
cation of proteins – N-glycosylation. The oxidation/
reductive conditions of the ER lumen ensure the for-
mation of disulfide bonds maintaining the tertiary 
and quaternary structure of proteins. The high level 
of functional chaperone proteins in the ER facilitates 
protein folding. The high Ca2+ concentration in the 
lumen is essential for Ca2+-dependent chaperones-
protein interactions. Any disturbance of these three 
determinants can lead to protein unfolding or mis-
folding [6]. 
Cells monitor protein folding by a protein 
quali ty control (QC) system is inbuilt in the ER and 
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the Golgi apparatus to maintain a balance between 
protein-folding capacity and protein-folding load, 
since a significant fraction of newly synthesized 
proteins in the ER fails to achieve a native confor-
mation. QC distinguishes unfolded or misfolded pro-
teins and sends them to a repeated folding cycle or 
selects terminally aberrant molecules for endoplas-
mic reticulum-associated degradation (ERAD) [7]. 
Excessive accumulation of proteins that are 
incorrectly conformed in the ER lumen causes ER 
stress. To guarantee the fidelity of ER functions, 
cells adjust QC system with a cascade of reactions – 
a specialised signaling network termed the unfolded 
protein response (UPR). Unfolded protein accumu-
lation triggers immunoglobulin binding protein/glu-
cose regulated protein-78 (BiP/GRP78) to dissociate 
from UPR sensors. UPR is mediated by three ER 
transmembrane sensors – receptors: activating tran-
scription factor 6 (ATF6), inositol reguiring kinase 1 
(IRE1) and double-stranded RNA-activated protein 
kinase (PKR) – like endoplasmatic reticulum kinase 
(PERK) [8]. To cope with accumulation of mis-
folded proteins these receptors trigger overlapping 
cascades of reactions: adaptation, alarm and apop-
tosis. During adaptation UPR strives to restore ER 
homeostasis, in particular through an attenuation of 
global translation and an activation of ERAD, which 
exports the aberrant proteins from the ER back into 
the cytosol, where they are degraded by the ubiqui-
tin-proteasome system. When adaptation of cells is 
unsuccessful, new signals are generated by the ER to 
induce cell death [9].
Protein N-glycosylation and processing in 
the ER are directly involved in protein folding, 
QC system, and ERAD. N-glycosylation is initi-
ated by bloc transfer of precursor oligosaccharide 
Glc3Man9GlcNAc2  to the Asn residue of a nascent 
polypeptide. After subsequent trimming of two resi-
dues of glucose, monoglucosylated oligosaccharide 
GlcMan9GlcNAc2 is recognized by lectin-like ER 
chaperones calnexin and calreticulin to facilitate 
protein folding. Cleavage of the last glucose resi-
due gives rise to glycan Man9GlcNAc2 on a native 
polypeptide and releases it from calnexin/calreticu-
lin cycle, while an incompletely folded conformer 
is reglucosylated to allow additional folding cycles. 
Terminally misfolded glycoproteins are subjected to 
mannose cleavage (until Man6-8GlcNAc2) and ERAD 
[10]. By this way some specific glycans-markers or 
glycocodes are formed to determine glycoprotein 
fate [11, 12].
The early stages of N-glycosylation at both 
sides of the ER membrane, producing the precursor 
of oligosaccharides Glc3Man9GlcNAc2, and ERAD, 
destroying newly synthesized misfolded or non-
assembled proteins, generate free oligosaccharides 
(FOS) – unbound structural analogues of glycans of 
glycoconjugates, their biosynthetic precursors and 
products of degradation. FOS appear also in lyso-
somal-endosomal system during degradation of ma-
ture glycoconjugates. The details of their formation 
in cells and precise structures from each source are 
well-known. FOS are also indentified in biological 
fluids [13]. Investigations of FOS in biological fluids 
have shown that their fractions specifically change 
in different diseases [14-16]. As FOS are generated 
by the ER and lysosomal-endosomal system, they 
might be able to reflect the functional status of these 
organelles. 
This work is devoted to specific glycocоdes 
generated by the ER and endosomal-lysosomal sys-
tem in the form of FOS to provide extracellular sig-
nals about their status and demands in health, aging 
and diseases. 
Materials and Methods
Plasma samples of practically healthy donors, 
patients with acute myeloproliferative neoplasms, 
patients suffering from cardiovascular disease were 
collected in SI Dnepropetrovsk Medical Academy. 
Plasma samples of healthy volunteers were obtained 
in the Glycobiology Institute of Oxford University. 
All the specimens were captured in accordance with 
the requirements of the relevant Ethics Committees. 
Plasma deproteinization and purification. Na-
tive plasma was precipitated with 10% trichloracetic 
acid (TCA) and centrifuged for 10 min at 3000 g to 
deproteinize, partially sterilize, and stabilize before 
transportation without lyophilisation. The further 
purification comprised filtration through a syringe 
with Millex-LH, 0.45 µm, filter (Millipore Corp., 
USA) or Amicon Ultra-0.5 ml Centrifugal Filter De-
vices (Millipore Corp., USA) to remove remaining 
protein, according to Alonzi et al. [17].
Porous graphitized carbon chromatography. 
After deproteinization, monosaccharides (mostly 
glucose) were removed using porous graphitized 
carbon (PGC from Thermo Electron, Runcorn, 
UK) chromatography with the column for 1 ml 
(25 mg/ml) according to the laboratory’s protocol. 
The column was pre-equilibrated twice with 1 ml 
of methanol, then twice with 1 ml of Milli-Q™ 
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H2O, twice with 1 ml of acetonitrile with 0.1% TFA 
(trifluoroacetic acid) and again twice with 1 ml of 
Milli-Q™ H2O. A sample (1.5 ml) obtained after fil-
tration through Millax®-LH 0.45 μm filter, was ap-
plied to the column and washed with 2 ml of Milli-
Q™ H2O. Oligosaccharides were eluted with 2 ml of 
0.1% TFA in acetonitrile-water mixture (1: 1 v/v). To 
change the solvent, the mixture was dried with a ro-
tary concentrator EYELA Vapour (Tokyo Rikakikai 
Co., LTD, Japan) and then with vacuum concentrator 
SPD SpeedVac (Thermo Scientific, USA).
Fluorescent labelling with 2-anthranilic acid 
(2-АА). Free carbohydrates were labelled with an-
thranilic acid (Sigma - Poole, Dorset, UK) as de-
scribed by Neville D.C.A. et al. [18]. Anthranilic 
acid (30 mg/ml) was dissolved in a mixture of 4% 
(w/v) trihydrate sodium acetate and 2% (w/v) of 
boric acid in methanol, 45 mg of sodium cyanobo-
rohydride were added and thoroughly mixed. This 
mixture was used as a labelling solution. Milli-Q™ 
H2O (30 µl) and 80 µl of the labelling solution were 
added to a sample dried in SpeedVac concentrator, 
stirred carefully and the reaction was carried out for 
1 h at 80 °C. The tube was cooled at room tempera-
ture and 1 ml of acetonitrile-water mixture (97:3, 
v/v) added.
removal of noncarbohydrate contaminants 
and unconjugated fluorescent dye. For purification 
after 2-AA labelling, a column Spe-ed SPE Cartrid-
ges Amide-2 (Applied Separations, USA) was used. 
Samples were loaded in 1 ml of acetonitrile-water 
mixture (97:3, v/v) using gravity flow and allowed to 
drip through the column. The column was washed 
twice with 1 ml of acetonitrile-water mixture (95:5, 
v/v). The labelled oligosaccharides were eluted twice 
with 0.75 ml of Milli-Q™ water and stored at -20 °C 
[17].
anion-exchange Separation of 2-aa labelled 
neutral and charged oligosaccharides. 2-AA la-
belled sugars were separated into neutral and 
charged glycans with QAE-Sephadex (Q25-120) 
chromatography[18]. QAE-Sephadex A-25 (acetate 
form, 200 μl) was placed in a 1.0 ml empty solid-
phase extraction (SPE) column (Applied Separa-
tions, USA). The column was pre-washed twice with 
1 ml of Milli-Q™ water and the 2-AA labelled sam-
ple was applied. The column was washed twice with 
1 ml of Milli-Q™ water. Neutral sugars were eluted 
twice with 1 ml of 0.5 M acetic acid, and anionic 
sugars were eluted twice with 1 ml of 0.5 M ammo-
nium ace tate. 2-AA labelled neutral oligosaccharides 
were dried using a vacuum centrifuge EYELA Va-
pour (Tokyo Rikakikai Co., LTD, Japan). After re-
suspending in 250 μl of Milli-Q™ water and adding 
250 μl of MeOH, 2-AA labelled neutral oligosaccha-
rides were dried using SPD SpeedVac Concentrator 
(Thermo Scientific, USA) to remove acetic acid. The 
2-AA labelled charged oligosaccharides were frozen 
with dry ice and lyophilized to remove ammonium 
acetate. Glycans of each fractions were resuspended 
in 100 μl of Milli-Q™ water. 
Digestion with sialidase. In order to investigate 
structures of the charged fraction, glycans of the 
fraction were digested with sialidase (artrobacter 
ureafaciens, OGS, UK) in accordance with the com-
pany’s instructions. 2-АА labelled glycans (100 µl) 
were dried in a vacuum concentrater SPD SpeedVac 
(Thermo Scientific, USA) and resuspended in 5 µl of 
appropriate buffer, then 5 µl of sialidase were added 
and the mixture was incubated at 37 °С for no less 
than 18 h. Glycan purification after the digestion was 
carried out using centrifugation through a Microcon 
column with Amicon®Ultra 0.5 ml Centrifugal Fil-
ter (Millipore, USA). The Microcon column was pre-
washed with 100 ml of Milli-Q™ H2O, centrifuged 
for 10 min at 15 000 g and removed into a clean tube. 
90 µl of Milli-Q™ H2O were added to the mixture 
of glycans with sialidase. The solution obtained was 
loaded into the Microcon column, centrifuged for 
10 min at 15 000 g and washed with 100 µl of Milli-
Q™ H2O by centrifugation as above. The centrifu-
gate was collected,  dried with a vacuum concen-
trater, and then resuspended in 100 µl of Milli-Q™ 
H2O.
2-AA labelled FOS from transferrin were used 
as an external standard for structural decoding.
High-Performance Liquid Chromatography 
(HPLC). Free oligosaccharides were analysed using 
HPLC after 2-AA labelling as described [18, 19]. 
The chromatography system consisted of a Waters 
Alliance 2695 Separations Module (USA) with the 
column 4.6×250 mm TSK gel-Amide 80 (Anachem, 
Luton, Beds, UK) and in-line Waters 474 Fluores-
cence Detector (USA) set at λex 360 nm and λem 
425 nm.
Glucose unit (GU) values were determined fol-
lowing comparison with a 2-AA labelled glucose 
oligomer ladder derived from a partial hydrolysate 
of dextran as an external standard. The data were 
collected and processed using Empower software.
To collect chromatographic data and process 
them computer programs Waters Millennium, Wa-
ters Empower, Peak Time, Microsoft Office Excel 
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2003/2007, Microsoft Power Point 2003/2007 were 
used.
Results and Discussion
Our investigation of serum FOS from healthy 
donors revealed that concentrations of these mole-
cules are very low, measured in several nanomoles 
per ml and differed quantitatively in each speci-
men. However, HPLC-profiles of these FOS un-
expectedly appeared to be quite stable with high 
qualitative reproducibility from sample to sample 
[20]. Fig. 1 (II) represents HPLC-profile of serum 
FOS of healthy donors in correspondent time in-
terval from 20 to 44 min to show free oligosac-
charides consisting of 4 and more monosaccharide 
residues (the lower sсale on the chromatogram). A 
comparison with an external standard – the par-
tially hydrolyzed dextran that can be seen in dot-
ted lines on the chromatogram – allowed molecular 
weight calculation of each species in glucose units 
(GU, the upper sсale) and then matching them up 
with the intracellular FOS which structures were 
well-known. Among intracellular FOS specified 
before [17], 11 glucosylated or non-glucosylated 
high-mannose counterparts (Glc0-3Man3-9GlcNAc1-2 ) 
were found for 12 identified serum species and sub-
species. There was no identified counterpart for the 
only species – the second peak. Separation of the 
total pool of FOS (Fig. 1, IIA) into neutral (Fig. 1, 
IIB) and charged (Fig. 1, IIC) fractions showed 
that most species (92.84 ± 0.15%) belonged to un-
charged glycans. The main species determining the 
shape of the whole chromatogram were the follo-
wing: 2 – with unknown structure, 4-Man4GlcNAc1 , 
6-Man5GlcNAc1(2) , 7-Glc1Man5GlcNAc1(2) . 
Detailed analysis of the neutral fraction and 
comparison of its glycans with those from diffe-
rent intracellular sources (Fig. 1, I) showed that 
they were authentic to cytosolic (Fig. 1, IA) or in-
traluminal (Fig. 1, IC) FOS from the dolichol phos-
phate cycle, and ERAD of glycans or glycoproteins 
(Fig. 1, IB). Thus, glycan Man4GlcNAc1 is generated 
on the cytosolic side of the ER membrane. Glycan 
Man5GlcNAc1  can appear from the cytosolic part of 
the dolichol phosphate cycle and both branches of 
ERAD. Glucosylated glycan Glc1Man5GlcNAc1 can 
be released only by ERAD. Some neutral species can 
also be generated by lysosome (Fig. 1, III) but their 
contribution is not more than 7-8%, taking into ac-
count digest effectiveness of lysosomal-endosomal 
system with regard to charged glycans. 
Analysis of the charged fraction revealed the 
presence of several species (1, 2, 3, 5, 6b, 10a) in 
low concentration (Fig. 1, IIC). Digestion of the 
charged glycans with sialidase and matching them 
up with external standards – oligosaccharides from 
transferrin with known structures – allowed us to 
define sialic acid-bearing species and decipher 
the structure of 10a that appeared to be a com-
plex type N-glycan with two residues of sialic acid 
(Sia2Gal2GlcNAc2Man3GlcNAc2 ). The most probable 
sources of these intracellular FOS derived from se-
rum samples are the lysosomes and endosomes that 
are involved in glycoconjugate digestion.
Our results show that, serum-derived neutral 
FOS appeared to originate mostly from ER and 
therefore points to ER functional or dysfunctional 
status. Serum-derived charged FOS might be genera-
ted by the lysosomal-endosomal system and could 
reflect physiological changes. To verify the idea that 
serum free oligosaccharides can serve as biomar-
kers of functionality of intracellular organelles, we 
performed assays on native models – human healthy 
aging, acute myeloproliferative neoplasms, and car-
diovascular diseases.
Human healthy aging. Serum FOS of healthy 
volunteers at the age of 22-25-year old and those 
of healthy donors at the age of 46-52-year old (de-
scribed above) were compared to evaluate sensitivity 
of HPLC-profiles of serum free oligosaccharides to 
aging changes inside the ER and lysosomal-endoso-
mal system.
There were 10 species identified in HPLC-pro-
files of serum FOS pool of healthy donors (Fig. 2, I). 
All the species have the same GU as their analogues 
in the second group (Fig. 2, III) and are marked with 
the same numbers on the chromatograms. Of these, 9 
were structural counterparts (Glc0-3Man3-9GlcNAc1-2) 
of the intracellular high-mannose FOS as deciphered 
before [17]. As in the case of serum FOS from 
healthy volunteers the second peak was structurally 
distinct from recognised intracellular FOS. 
Separation of the total pool of FOS (Fig. 2, 
IIA) into neutral (Fig. 2, IIB) and charged (Fig. 2, 
IIC) fractions revealed that like in the case of serum 
FOS of practically healthy donors (Fig. 2, IIIB) most 
of the species of HPLC-profiles were uncharged 
glycans. But unlike FOS of practically healthy 
donors, the main species were: 4-Man4GlcNAc1 , 
6 -Man 5GlcNAc1(2)  ,  7- Glc1Man 5GlcNAc1(2)  , 
8-Man6GlcNAc1(2)  or/and Glc3Man4GlcNAc1 . 
The charged serum FOS of healthy volun teers 
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was represented with one species: a complex 
type N-glycan with two residues of sialic acid 
(Sia2Gal2GlcNAc2Man3GlcNAc2 ).
Comparison of HPLC-profiles of neutral frac-
tions in both groups with intracellular sources of 
FOS showed interesting regularities reflecting dis-
tinct processes occurring in ER with aging. The 
peak area of species 4 (Man4GlcNAc1 ) with respect 
to a peak area of species 6 (Man5GlcNAc1 ) increased 
in the group of healthy donors in comparison with 
the group of healthy volunteers (Fig. 2, IB and IIIB). 
As Man4GlcNAc1 is synthesized on the cytosolic 
side of the ER membrane and must be converted 
into Man5GlcNAc1 during dolichol-mediated gly-
cosylation, an increasing of concentration of free 
Man4GlcNAc1  means that it cannot be transformed 
into next metabolite with the same rate. This indi-
cates that the dolichol phosphate cycle is less com-
petent with aging. The appearance of FOS with 7 
and more mannose residues on the chromatogram of 
the second group (Fig.2, IIIB), while they are absent 
on the chromatogram of the first group (Fig. 2, IB) 
make it clear that ERAD of intralumenal ER glycans 
and glycoproteins is intensified with aging. Addi-
tion of more species (Fig. 2, IIIC) to the main gly-
can (Sia2Gal2GlcNAc2Man3GlcNAc2 ) of the charged 
fraction (Fig. 2, IC) demonstrates an aging-induced 
perturbation in lysosomal-endosomal system. 
acute myeloproliferative neoplasms. Serum 
FOS of patients suffering from acute lymphoblas-
tic leukemia, acute myelomonocytic leukemia, and 
acute phase of preleukemic syndrome were ana-
lyzed.
In acute oncotransformation of bone marrow 
cells chromatographic spectra of serum FOS had 
some individual features, but common ones were 
much more pronounced. There were only 5 main 
species identified in HPLC-profiles of serum FOS 
pool:  6, 7, 8, 9 and 10a (Fig. 3, IA). The first two 
species (6 and 7) had very low concentrations, and in 
some samples 7 was not identified at all.
Separation of the total pool of FOS (Fig. 3, 
IA) into neutral (Fig. 3, IIB) and charged (Fig. 3, 
IIC) fractions revealed that in neutral fraction the 
only species identified were: 6-Man5GlcNAc1(2), 
7-Glc1Man5GlcNAc1(2) , 8-Man6GlcNAc1(2) or/and 
Glc3Man4GlcNAc1 , 9-Man7GlcNAc1(2). Charged se-
rum FOS were represented with 2 main species: 9 – 
a complex type N-glycan with one residue of sialic 
acid (Sia1Gal2GlcNAc2Man3GlcNAc2 ) and 10a – a 
complex type N-glycan with two residues of sialic 
acid (Sia2Gal2GlcNAc2Man3GlcNAc2).
Comparison of serum FOS HPLC-profiles of 
patients suffering from acute myeloproliferative 
neoplasms with those of healthy donors (Fig. 3, 
IIIB) showed reduction or even almost complete 
disappearan ce of the main species that define 
HPLC-profiles of healthy donors: 4-Man4GlcNAc1 , 
6-Man5GlcNAc1(2) , 7-Glc1Man5GlcNAc1(2). At 
the same time concentrations of two species: 
8-Man6GlcNAc1(2)  or/and Glc3Man4GlcNAc1 , 
9-Man7GlcNAc1(2)  were substantially increased.
Analysis of intracellular sources of FOS (see 
Fig. 3, II, IV) revealed an inhibition of the dolichol 
phosphate cycle on both sides of the ER membrane 
and intensification of ERAD in acute myeloprolife-
rative neoplasms. Total depression of protein syn-
thesis indicates activation of PERK branch of UPR, 
and ERAD activation points at involvement of ATF6 
branch [21].
Appearance of the complex type N-gly-
can with one residue of sial ic acid 
(Sia1Gal2GlcNAc2Man3GlcNAc2 ) in the charged 
fraction of serum FOS in acute myeloproliferative 
neoplasms can be explained by decreasing the neu-
raminidase-1 activity and  increasing lysosomal exo-
cytosis [22]. 
Cardiovascular pathologies. Serum FOS of 
2 groups of patients suffering from ischemic heart 
disea se and arterial hypertension were analyzed. 
The patients of the first group had no systolic dis-
turbances, while the patients of the second group 
combined arterial hypertension and ischemic heart 
disease with chronic systolic heart failure. All the 
profiles obtained differed from each other and had 
their own individual features. Some typical chroma-
tograms are represented on Fig. 4.
HPLC-profiles of serum FOS of the patients 
included the same 12 species that had been found 
in the healthy donor’s profile, but their ratios were 
completely different (Fig. 4, I, II, IV, V). In heart 
diseases the cells are often under such threats as oxi-
dative stress, hypoxia, and glucose deprivation [23]. 
That is why the deep transformations of FOS profiles 
in cardiovascular disease had been expected. These 
transformations were observed both in neutral and 
charged fractions (Fig. 4, IB and C, IIB and C, IVB 
and C, V B and C).
The transformations depended on the se-
verity of the disease. In the case of ischemic 
heart disease and arterial hypertention the ra-
tio among Man4GlcNAc1 , Man5GlcNAc1(2), and 
Glc1Man5GlcNAc1  (4, 6, and 7 species of neutral 
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fractions), that are the main species of the control 
profile, as a rule, remained the same (Fig. 4, IB, IIB). 
In the case of chronic heart failure this ratio 
was not substantiated (Fig. 4, IVB, VB). A set of 
other changes is connected with substantial en-
largement of peak area for 5 and 6b species with 
the structures Man5GlcNAc1/Glc1Man4GlcNAc1 and 
Man4GlcNAc2, respectively. 
In spite of great individual differences all the 
profiles in both groups had some common features. 
Two main enlarged glycan species in the neutral 
fraction (8 and 9) and one peak in the charged frac-
tion (3) distinguished the FOS of the patients from 
those of the practically healthy donors. The neutral 
marker species appeared to be represented by high-
mannose glycans Man6GlcNAc1(2)/Glc3Man4GlcNAc1, 
and Man7GlcNAc1(2) (Fig. 4, I, II, IV, V marked in 
circles). The structure of the 3 of the charged frac-
tion is unknown.
In ischemia and in chronic systolic heart fai-
lure all three branches of UPR are known to be ac-
tivated. IRE-1α can promote both prosurvival and 
proapoptotic pathways. ATF6 leads to transcrip-
tion of ER stress responsive genes (ER chaperones, 
GRP78), ERAD activation and to cardiomyocyte cell 
survival. Initially PERK reduces the load on the ER 
folding machinery, but under prolonged ER stress 
PERK switches to the promotion of apoptosis and 
may contribute to heart failure [24, 25].
The transformations of serum FOS HPLC-pro-
files in cardiovascular disease showed ERAD inten-
sification in all the cases investigated that indicated 
by an increase of 8 and 9 species in all the samples. 
It means that ATF6 branch and prosurvival pathways 
of IRE1 branch are switched on. The FOS HPLC-
profiles could not reveal total suppression of protein 
synthesis by switches between these branches and 
PERK as the glycan Man4GlcNAc1 was present in 
all spectra indicating a continued support of the 
dolichol phosphate cycle. Our findings are agreed 
with the idea that progression of a disease depends 
on dynamics of UPR branches rather than a switch 
between them [26].
These findings have led us to the conclusions 
that serum free oligosaccharides being tightly con-
nected to intracellular processes in certain cellular 
organelles and  being able to reflect specifically per-
turbations in the ER and endosomal-lysosomal sys-
tem under wide range of stressors can serve as extra-
cellular markers of the ER and endosomal-lysosomal 
system functionality. 
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Глікомаркери стресу 
ендоплазматичноГо 
ретикулума і лізосомно-
ендосомної системи в 
сироватці крові людини при 
старінні та захворюваннях
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Для перевірки гіпотези, чи можуть 
позаклітинні вільні олігосахариди відображати 
функціональний стан ендоплазматичного ре-
тикулума (ЕР) і ендосомно-лізосомної систе-
ми, ВЕРХ-спектри вільних олігосахаридів 
сироватки крові людини при старінні, го-
стрих мієлопроліферативних новоутвореннях 
і серцево-судинних патологіях порівнювали 
із внутрішньоклітинними гліканами. 
Після депротеїнізації і очищення вільних 
олігосахаридів сироватки крові людини їх 
маркували антраніловою кислотою, поділяли 
на нейтральні і заряджені за допомогою 
хроматографії на QAE сефадексе (Q25-120) і 
аналізували методом ВЕРХ. Для аналізу гліканів 
зарядженої фракції їх розщеплювали сіалідазою 
і порівнювали з олігосахаридами трансфе-
рину. ВЕРХ-спектри вільних олігосахаридів 
сироватки крові виявили: за старіння – 
помірне гальмування циклу доліхолфосфату 
в ЕР, посилення асоційованої з ЕР деградації і 
деградації в ендосомно-лізосомній системі; за 
гострих мієлопроліферативних новоутворень – 
інгібування циклу доліхолфосфату, посилен-
ня асоційованої з ЕР деградації і підвищення 
лізосомального екзоцитозу; у разі серцево-су-
динних патологій – посилення асоційованої 
з ЕР деградації і деградації глікокон’югатів 
ендосомно-лізосомною системою. Показано, що 
вільні олігосахариди сироватки крові виявля-
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ють специфічні зміни ЕР і ендосомно-лізосомної 
системи за дії широкого спектра стресорних 
факторів і, певно, можуть бути позаклітинними 
маркерами функціонального статусу цих органел.
К л ю ч о в і  с л о в а: вільні олігосахариди, 
ВЕРХ-спектри гліканів, стрес ЕР, асоційована з 
ЕР деградація протеїнів, порушення лізосомно-
ендосомної системи, глікомаркери.
Гликомаркеры стресса 
эндоплазматическоГо 
ретикулума и лизосомно-
эндосомной системы в 
сыворотке крови человека 
при старении и заболеваниях
И. Ю. Письменецкая1, Т. Д. Баттерс2
1ГУ «Днепропетровская медицинская 
академия», Украина;
2CarboNet Consulting Ltd., Оксфорд, 
Великобритания;
e-mail: ip01589@gmail.com
Чтобы проверить гипотезу, могут ли вне-
клеточные свободные олигосахариды отражать 
функциональное состояние эндоплазматическо-
го ретикулума (ЭР) и эндосомно-лизосомной 
системы, ВЭЖХ-спектры свободных олигосаха-
ридов сыворотки крови человека при старении, 
острых миелопролиферативных новообразова-
ниях и сердечно-сосудистых патологиях срав-
нивали с внутриклеточными гликанами. После 
депротеинизации и очистки свободных олиго-
сахаридов сыворотки крови человека их метили 
антраниловой кислотой, разделяли на нейтраль-
ные и заряженные с помощью хроматографии на 
QAE Сефадексе (Q25-120) и анализировали ме-
тодом ВЭЖХ. Для анализа гликанов заряженной 
фракции их расщепляли сиалидазой и сравни-
вали с олигосахаридами трансферрина. ВЭЖХ-
спектры свободных олигосахаридов  сыворотки 
крови выявили: при старении – умеренное тор-
можение цикла долихолфосфата в ЭР, усиление 
ассоциированной с ЭР деградации и деградации 
в эндосомно-лизосомной системе; при острых 
миелопролиферативных новообразованиях – ин-
гибирование цикла долихолфосфата, усиление 
ассоциированной с ЭР деградации и повышение 
лизосомального экзоцитоза; при сердечно-сосу-
дистых патологиях – усиление ассоциированной 
с ЭР деградации и деградации гликоконъюгатов 
эндосомно-лизосомной системой. Показано, 
что свободные олигосахариды сыворотки кро-
ви выявляют специфические изменения ЭР и 
эндосомно-лизосомной системы при действии 
широкого спектра стрессорных факторов, и, ве-
роятно, могут быть внеклеточными маркерами 
функционального статуса этих органелл. 
К л ю ч е в ы е  с л о в а: свободные олиго-
сахариды, ВЭЖХ-спектры гликанов, стресс ЭР, 
ассоциированная с ЭР деградация протеинов, 
нарушения лизосомно-эндосомной системы, 
гликомаркеры.
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